(RTTNews) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). This marks the launch of the first BioMed X Institute in the US, to be located in New Haven, Connecticut.
BioMed X noted that the new US-based research collaboration will focus on immunology and tissue engineering, following a first joint research project on Alzheimer's disease at the BioMed X Institute in Heidelberg, Germany.
The company stated that the new BioMed X Institute will be managed by Mark Johnston, an experienced biotech entrepreneur and business leader who recently joined BioMed X.
The current partnership with AbbVie is focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) from primary human cells and tissues to study human tissue inflammation.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
